Subscriber access provided by EMORY UNIV
Article
Study of the preparation of amorphous Itraconazole formulations María P. Fernández-Ronco, Matteo Salvalaglio, Johannes Kluge, and Marco Mazzotti Cryst. Growth Des., Just Accepted Manuscript • DOI: 10.1021/cg501892j • Publication Date (Web): 13 Apr 2015 Downloaded from http://pubs.acs.org on April 20, 2015
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Crystal Growth & Design is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
Study of the preparation of amorphous Itraconazole formulations Mar´ıa P. Fern´andez-Ronco,∗,†,¶ Matteo Salvalaglio,†,‡ Johannes Kluge,†,§ and Marco Mazzotti† ETH Zurich, Institute of Process Engineering, Sonneggstrasse 3, 8092 Zurich, Switzerland, and Facolt` a di Informatica, Istituto di Scienze Computazionali Universit` a della Svizzera Italiana, 6900 Lugano, Switzerland E-mail:
[email protected] Phone: +41 44 632 22 45. Fax: +41 44 632 11 41
Abstract The formulation of poorly water-soluble Active Pharmaceutical Ingredients (APIs) has been widely studied in the last decades to overcome the limited bioavailability imposed by these pharmaceutical ingredients. In this work, supercritical fluid extraction of emulsions has been applied using two different types of excipients, i.e. polyvinyl alcohol (PVA) and glycyrrhizic acid (GA) to address the precipitation of itraconazole (ITZ) as an amorphous solid. The delivery profiles of the in-vitro dissolution tests of the ITZ-GA particles confirmed the advantage of the manufactured amorphous material in terms of apparent solubility in comparison to the raw itraconazole. Furthermore, the stability of an amorphous glassy product and its potential to recrystallize ∗
To whom correspondence should be addressed ETH Zurich–Institute of Process Engineering ‡ ETH Zurich–Istituto di Scienze Computazionali ¶ Current address: EMPA, Laboratory for Advanced Fibers, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland. E-mail:
[email protected] § Current address: Novartis Pharma AG, 4056 Basel, Switzerland. †
1 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
in the presence of water have been experimentally determined using both excipients and interpreted applying molecular dynamics (MD) simulations. Results manifest that recrystallization of the amorphous ITZ particles starts at their surface, corroborating that the better adsorption of GA into the surface of the particles inhibits the crystallization and provides long term stability products. This study shows the importance of the selection of the excipient in the preparation of amorphous formulations of API’s, as well as their effect on the stability to recrystallize over storage or dosing in the presence of water.
2 ACS Paragon Plus Environment
Page 2 of 35
Page 3 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
1
Introduction
2
The formulation of poorly water-soluble active pharmaceutical ingredients (APIs) exhibiting
3
low and erratic bioavailability represents a major challenge in pharmaceutical development.
4
In fact, about 30% of approved drugs, as compared to 40 - 70% of new chemical entities
5
(NCEs) currently under development, belong to this category.
6
Classical formulation development has worked out a number of strategies to overcome the
7
issue of limited bioavailability, including the reduction of API particle size, the modification
8
of API solid form, i.e. the formation of polymorphs as well as of salts and co-crystals, and
9
the association of the API with a well-soluble carrier (e.g. the formation of drug-polymer
10
solid dispersions, cyclodextrin inclusion complexes and self-emulsifying systems). Some of
11
these approaches involve a change of the physical state of the drug, namely from the crys-
12
talline to a high-energy amorphous state, which promises an enhancement of bioavailability
13
by increasing both the apparent solubility and the rate of dissolution of the API 1 . However,
14
the main drawback of amorphous formulations, as solid dosage forms and/or as suspen-
15
sions, lies in their inherent physical metastability and the associated risk of uncontrolled
16
API recrystallization during their preparation and storage as well as during dissolution/re-
17
suspension 2,3 . This means that such formulations may reach the market only if the time scale
18
of recrystallization is large enough that sufficient stability of the pharmaceutical product can
19
be guaranteed 4 . In many cases, this is only feasible if stabilizing excipients are added and
20
adequate storage conditions are defined.
21
The formation of amorphous particles by supercritical CO2 (scCO2 ) is a common and
22
widely used practice in the pharmaceutical literature. Several are the publications dealing
23
with the use of precipitation by compressed antisolvent (PCA) technique, where the scCO2
24
acts as an antisolvent agent of the API, generating high supersaturations which usually lead
25
to the precipitation of solid amorphous particles 5,6 . Morevover, the formation of particles
26
through emulsions, combined with the use of supercritical CO2 as solvent extracting agent, is
27
well-established in the literature, particularly in the formulation of amorphous solids such as 3 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
28
polymeric materials and drug-polymer composites 7,8 . This Supercritical Fluid Extraction of
29
Emulsions (SFEE) process should be applicable also in the formulation of sparingly soluble
30
APIs, aiming at an aqueous suspension of submicron and amorphous API particles that is
31
both highly supersaturated and finely dispersed, so as to maximize bioavailability. However,
32
since also the recrystallization of API from supersaturated amorphous suspensions has been
33
observed 9,10 , adequate stabilization of such suspensions remains a challenge. Recent studies
34
have also shown the role that the particle’s surface plays in this context. For example, in
35
the recrystallization of phenanthrene from emulsions 10 , it has been observed that this pro-
36
cess is triggered by surface contact of amorphous particles with already existing crystals.
37
In another study concerning the recrystallization of celecoxib from amorphous particles 11 ,
38
it was concluded that crystallization of celecoxib mostly originates on the particle surface
39
exposed to the aqueous medium, where it can be successfully inhibited by irreversibly ad-
40
sorbing ammonium glycyrrhizinate molecules from the surrounding solution. Ammonium
41
glycyrrhizinate, the excipient used in that paper, is also investigated in the present study.
42
With an extremely low aqueous solubility of 98%, Fig 1a), was purchased from TCI Chemicals (Tokio, Japan). Both excip-
62
ients glycyrrhizic acid ammonium salt (GA) and polyvinyl alcohol Mowiol 4-88 (PVA), whose
63
molecular structures can be compared in Fig. 1b and c, as well as HPLC grade acetonitrile
64
(ACN), triethylamine (TEA), and hydrochloric acid (37%), were supplied by Sigma Aldrich
65
(Buchs, Switzerland). Sodium chloride for simulated gastric fluid and dichloromethane
66
(DCM), employed in emulsion preparation, were obtained from Merck (Darmstadt, Ger-
67
many). CO2 of 99.9 % purity was supplied from PanGas (Dagmersellen, Switzerland).
68
Preparation of glassy itraconazole
69
Glassy itraconazole was prepared by melt quenching as follows: 1 g of crystalline itraconazole
70
is melted by heating up above the melting temperature, i.e. 166 ◦C, in a Petri dish followed
71
by a quick cooling of the molten liquid by pouring liquid N2 over it. Afterwards, the glassy
72
drug is scratched and ground by mortar and pestle to produce a fine glassy ITZ powder whose
73
lack of crystallinity was confirmed by XRD and DSC measurements. The final product was
74
then stored in a desiccator at room temperature until further use.
5 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
75
Preparation of itraconazole emulsions
76
An oil in water emulsion (o/w) was prepared by pouring at room temperature the organic
77
phase, consisting of a 5 wt% itraconazole in dichloromethane solution, into the water phase,
78
which contains 1.2 wt% excipient, i.e. GA or PVA. The final mixture, containing both
79
phases at a weight ratio of 1:4, respectively, was then mixed by ultrasonication using a
80
BransonSonifier 450 (Skan AG, Basel, Switzerland). Sonication was applied at maximum
81
power output while cooling the emulsion on ice and stirring with a magnetic stir bar at 500
82
rpm. For 200 mL of emulsion, a sonication time of 2 minutes was applied in 4 cycles of 30
83
seconds each; intermediate breaks allowed for sufficient cooling of the emulsion
84
Supercritical Fluid Extraction of Emulsions (SFEE)
85
Directly after the preparation of the emulsion, the organic solvent was extracted from the
86
emulsion by SFEE, a process where supercritical CO2 acts as an extracting solvent agent of
87
the solvent contained in the emulsion droplets, i.e. DCM in this case, so as to produce solid
88
particles of the API. A scheme of the experimental setup used for SFEE experiments and a
89
more detailed description of the process is provided in a previous work 8 . Briefly, both CO2
90
and emulsion are delivered from their storage vessels at continuous flowrates of 80 g/min
91
and 2 mL/min, respectively. The two streams are mixed in a coaxial nozzle located at the
92
entrance of a high pressure vessel, i.e. the emulsion stream is finely dispersed by the much
93
larger stream of scCO2 , thus creating conditions where DCM is extracted selectively and
94
efficiently from the droplets of the organic phase. Throughout the experiment, the vessel
95
is kept at constant pressure and temperature, i.e. 80 bar and 45 ◦C, by means of a back-
96
pressure regulator and a thermostat, respectively. While the stream of supercritical CO2
97
leaves the reactor together with the organic solvent through an outlet located at the top of
98
the vessel, a solvent free aqueous suspension of itraconazole particles is recovered through a
99
separate outlet at the bottom of the reactor. The product suspension is then stored at room
100
temperature for specific time intervals, tlag , prior to its post-processing. 6 ACS Paragon Plus Environment
Page 6 of 35
Page 7 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
101
Post-processing of SFEE product suspensions
102
For sample characterization, solid particles were recovered from the aqueous suspension
103
and separated from the free surfactant remaining in solution by means of centrifugation
104
and freeze-drying. After centrifugation at 20,000 rpm for 15 min (Avanti J-20, Beckman,
105
USA) the supernatant was discarded. Sedimented particles were re-suspended in 2 mL of
106
cold deionized water and frozen immediately by liquid N2 . Subsequently, freeze-drying was
107
carried out in a FlexiDry equipment (FTS Systems, USA) for 24 hours, and the collected
108
dried particles, containing less than 50 ppm of DCM, were stored at room temperature in a
109
desiccator for further characterization.
110
Precipitation by compressed antisolvent (PCA)
111
The precipitation of itraconazole by PCA was carried out mixing a stream of CO2 , which is
112
drawn from a dip tube cylinder and precooled in a pressure module (PM101, NWA GmbH,
113
L¨orrach, Germany) before being delivered to the reactor by a piston pump (PP200, Thar
114
Design Inc., Pittsburgh, USA), and the DCM solution containing the ITZ, which is delivered
115
by an HPLC pump (PU2080 plus, Jasco, Easton, USA). Both the CO2 and the solution feed
116
stream are mixed by a two substance nozzle (Schlick, Untersiemau, Germany) at the inlet
117
of the reactor (Premex, Lengnau, Switzerland). The streams are brought to the operating
118
temperature by a thermostat (CC230, Huber, Offenburg, Germany). The solid particles
119
precipitated are retained within the reactor by a filter bag made of Teflon tissue, and two
120
sintered metal filters are placed at the outlet of the reactor in order to remove all particles
121
from the off-gas stream. A more in detail description of the process and of the experimental
122
setup employed can be found elsewhere 8,14 .
7 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
123
Characterization of Itraconazole content
124
For particles, a known amount of the freeze-dried powder was dissolved in DMSO, and the
125
solution was filtered using a PTFE 0.22 µm syringe filter and loaded into HPLC vials. The
126
itraconazole content of the resulting solution was determined by high-performance liquid
127
chromatography on an Agilent 1100 (Agilent Technologies, USA) with a DAD detector.
128
Itraconazole was detected at 263 nm using as eluent acetonitrile:water (70:30 v/v) + 0.05%
129
TEA with a flow rate of 1 mL. At these conditions, and using a GROMSIL 100 ODS-2 FE
130
column (125 × 4.6 mm), the peak of ITZ eluted at 3.2 min. Using the same chromatographic
131
method and static phase, the ITZ concentration of the aqueous samples collected from in-
132
vitro tests was also determined.
133
SEM, DSC and XRD analysis
134
Scanning electron microscopy (SEM) images of samples, previously sputter-coated with 5 nm
135
platinum, were carried out in a Zeiss Gemini 1530 FEG scanning electron microscopy to
136
analyse their morphology. Differential scanning calorimetry (DSC) measurements were con-
137
ducted by using a Mettler Toledo DSC 822e. Indium was used for calibration. Accurately
138
weighed samples (5 mg to 10 mg) were placed in hermetically sealed aluminium crucibles and
139
scanned from 20 ◦C to 220 ◦C at a rate of 5 ◦C/min under nitrogen purge. To determine the
140
degree of crystallinity of different products, X-ray diffraction (XRD) patterns were obtained
141
on a Bruker AXS D8 Advance diffractometer with Cu Kα radiation (λ = 1.5406 ) and a
142
voltage and current applied of 40 kV and 30 mA, respectively. The crystallinity of samples
143
was calculated by minimizing the square error of the linear regression of the XRD patterns
144
in the 2θ range of 6◦ to 60◦ , namely raw ITZ (100 % crystalline), excipient, and glassy ITZ
145
(100% amorphous), whose summation constitute the pattern of the SFEE product.
8 ACS Paragon Plus Environment
Page 8 of 35
Page 9 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
146
In-vitro drug dissolution test
147
In-vitro itraconazole dissolution data was obtained by means of a dialysis method 15 as fol-
148
lows: 5 mg of the corresponding ITZ product were mixed with 10 mL of simulated gastric
149
fluid without pepsin 16 and placed inside a semipermeable regenerated cellulose dialysis tube
150
(length 10 cm, ID = 4.5 cm, CO = 14,000), which was closed at both ends with a clamp to
151
form a tight bag and to avoid any contamination. Then, the bag was immersed in 250 mL
152
of the dissolution medium, i.e. simulated gastric fluid, and kept at 37 ◦C in a shaking water
153
bath at a speed of 60 rpm. Aliquots of 5 mL were withdrawn from the dissolution medium at
154
specific time intervals and replaced by the same volume of fresh simulated gastric fluid. After
155
filtration with a 0.22 µm PTFE filter, the ITZ content of the samples was directly analysed
156
by HPLC according to the method previously described. Experiments were replicated twice
157
and the average values reported.
158
Molecular Dynamics simulations
159
For the investigation of the surface recrystallization in water, a small amorphous particle
160
of ITZ was simulated using classical molecular dynamics (MD). The initial structure was
161
prepared using the open source software packmol 17 in order to randomly arrange 230 ITZ
162
molecules in a spherical aggregate characterized by a radius of approximately 4 nm. Such a
163
structure has been solvated in a box of TIP3P 18 water molecules resulting in a symulation box
164
composed of 72,618 atoms. The system was then relaxed with a 2,000 cycles minimization.
165
Temperature and pressure were then equilibrated with a 1 ns simulated annealing and a
166
subsequent 5 ns NPT calculation, respectively. A NVT production run of 300 ns was then
167
performed in order to characterize the dynamic evolution of the ensemble of ITZ molecules.
168
In order to investigate the excipient interaction with the ITZ surface, a small slab composed
169
of 40 ITZ molecules has been prepared and solvated with TIP3P water molecules following
170
the same protocol used in the preparation of the particle model previously described. The
171
simulation boxes resulted approximately in 10,000 atoms per simulation. As a potential 9 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
172
energy function, the Generalized Amber Force Field (GAFF) 19,20 was chosen. The ITZ
173
and GA structures were obtained from their crystal structure and optimized with Density
174
Functional Theory (DFT) calculations performed at the B3LYP/6-31G(d,p) level 21 . The
175
structure of the PVA oligomer has been constructed by replicating the monomer structure
176
optimized within a small chain of three monomer units. The partial atomic charges of ITZ,
177
GA and PVA were assigned using the restrained electrostatic potential formalism 22 based
178
on the electrostatic potential computed with DFT at the B3LYP/6-31G(d,p) level. All DFT
179
calculations were carried out using Gaussian 09 23 . In the MD simulations, we applied three-
180
dimensional periodic boundary conditions. Long range electrostatics were treated with the
181
Particle Mesh Ewald (PME) approach and a non-bonded cut-off of 1.0 nm was used 24 . The
182
shake algorithm 25 was used to constrain the length of hydrogen bonds, thus enabling a 2 fs
183
time step. The MD simulations were performed with the AMBER 12 suite of programs 26 .
184
Minimization was performed with the sander MD engine, while the equilibration and the
185
production runs were performed using pmemd engine on a GPU workstation 24 .
186
Results and Discussion
187
A first set of experiments addressed the feasibility and reproducibility of SFEE-based process
188
as means to manufacture suspensions of amorphous itraconazole particles using two different
189
excipients at otherwise identical operating conditions. The expected enhanced solubility
190
of the manufactured amorphous particles in comparison to the crystalline raw API was
191
confirmed by conducting in-vitro dissolution tests. In a second part of the study, the effect
192
of the excipients in the stabilization of aqueous suspensions of amorphous pure glassy ITZ
193
was evaluated experimentally and rationalized by means of molecular dynamics simulations.
10 ACS Paragon Plus Environment
Page 10 of 35
Page 11 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
194
Supercritical processing for Itraconazole amorphization
195
To investigate the potential of different supercritical CO2 based technologies to produce
196
amorphous itraconazole products, three different experiments were carried out (Table 1).
197
In Run 1, the precipitation of raw itraconazole as a solid powder from a dichloromethane
198
solution was evaluated by compressed antisolvent (PCA) technique using experimental con-
199
ditions based on earlier studies 27 . Runs 2 and 3 addressed the use of supercritical CO2
200
as solvent extracting agent of an emulsion containing the low-water soluble itraconazole by
201
SFEE technique. This process leads to an aqueous suspension of formulated particles, i.e.
202
ITZ-excipient, that might be post-processed to obtain a solid product. Both Runs 2 and 3
203
were conducted at identical operating conditions, while the excipient used as surfactant in
204
the emulsion preparation changed from PVA in Run 2 to GA in Run 3.
205
Figures 2 and 3 show representative SEM images of the solid powders recovered from all
206
experimental runs. As it can be observed in Figure 2, the product collected after Run 1 con-
207
sists of rather big crystalline particles, whereas Runs 2 and 3 yield both ITZ particles much
208
smaller in size than those of Run 1, varying from flake like morphologies when PVA was
209
used as excipient to spherical microparticles using GA. Besides, the degree of crystallinity of
210
these products (fig. 4) shows that contrary to what happened using PCA (crystallinity ca.
211
100%), the products recovered from SFEE processing were amorphous or semi-crystalline
212
depending on the excipient.
213
It is important to notice that the fundamental difference between PCA and SFEE is the
214
precipitation mechanism. Whereas in PCA the precipitation of the particles starts in a ho-
215
mogeneous solution, therefore the size of particles depends on the supersaturation during
216
mixing and on the nucleation and growth kinetics, in SFEE technique the nucleation and
217
growth are confined within the droplets of the emulsion. As a result, the particle size of the
218
final product is typically smaller than that obtained by PCA 7 , as it was confirmed in our
219
experiments. Moreover, PCA is certainly the technique that generates higher supersatura-
220
tion compared to SFEE, therefore, the precipitation of amorphous ITZ particles would be 11 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
221
expected at the conditions described for Run 1, i.e. 100 bar and 40 ◦C, which characterize
222
a system above the critical point of the binary CO2 -DCM mixture at this temperature (81
223
bar) 28 . However, it seems obvious at the light of our results for Run 1 that not only high
224
supersaturation is required to produce amorphous ITZ particles, but also a good stabiliza-
225
tion of these amorphous particles, once formed, is an important requirement that has to be
226
taken into account.
227
The results from Runs 2 and 3 seem to indicate that the use of excipients might promote
228
this stabilization, but its selection is a key parameter for a successful effect. For example,
229
considering the products recovered at different tlag , i.e. the time lag between the collection
230
of the suspension product after the SFEE processing and its post-processing, this time can
231
offer a way to compare the stability of the manufactured suspension over time, hence the
232
stabilization effect of the excipient. Figure 4 shows that the product precipitated in Run 3
233
using GA as excipient is amorphous and stable over time. Besides, it contains 19wt.% of
234
GA according to the HPLC measurements. On the contrary, the collected ITZ-PVA semi-
235
crystalline particles, which contain 3wt.% of PVA, increased their degree of crystallinity
236
from 63% to 75% in 20 hours, thus indicating a recrystallization effect during this time, and
237
therefore the lack of stability of such ITZ formulation.
238
Analysing in detail the morphology of the ITZ-PVA particles for a tlag of 0 hours, some
239
spheres associated to amorphous state are still visible (see insert in fig. 3d) which exhibit a
240
rougher surface than that of the spheres obtained using GA as excipient. Coupling this ob-
241
servation with the appearance of some rougher particles at high tlag when employing GA (see
242
insert in fig. 3c) and with the conclusions reported by other authors who observed crystal-
243
lization triggered at the surface of the particles 10,11 , both facts suggest that recrystallization
244
of the amorphous material starts indeed at the surface. This preliminary hypothesis about
245
the recrystallization mechanism in an amorphous particle will be analysed later in detail.
12 ACS Paragon Plus Environment
Page 12 of 35
Page 13 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
246
In-vitro dissolution tests
247
In order to evaluate whether the apparent solubility of the amorphous ITZ-GA product man-
248
ufactured by SFEE is higher than that of the crystalline raw API, in-vitro drug dissolution
249
tests were conducted using both solid materials.
250
It is expected that the apparent solubility of ITZ-GA experiences a significant increase
251
due to the combined effect of the reduction in particle size, amorphization and association
252
of the API with the excipient. In fact, Sun et al. 29 reported an increase of five-fold in the
253
percentage of itraconazole dissolved by reducing the average particle size of the tested product
254
from 5.5 µm to 300 nm. Barret et al. 6 analysed the effect of Polyethylene glycol (PEG) as
255
excipient to assist the precipitation of itraconazole, concluding that for itraconazole-PEG
256
(50:50) particles, the percentage of itraconazole dissolved in the dissolution test was 2.7 times
257
higher after 100 minutes; and the amorphous state of APIs is well-known to significantly
258
promote an increase in the apparent solubility of the drug 30 . In particular for pure ITZ, the
259
supersaturation at 37 ◦C has been theoretically calculated and established between 95 and
260
125 31 .
261
Figure 5 shows the evolution in the delivery of ITZ-GA in comparison to raw ITZ, where
262
bars indicate the deviation of two experimental measurements and straight lines guide for
263
the eyes. Results highlight the higher apparent solubility of ITZ-GA product that reaches
264
concentrations of 6.42 ppm after 1,600 minutes in comparison to 0.66 ppm of the crystalline
265
ITZ over the same delivery period. Due to the lack of experimental data points in the interval
266
between 200 - 1,000 minutes, the kinetic evaluation of the global curve is not possible.
267
Nevertheless, the initial linear part of the curves, i.e. from zero to ca. 60 minutes, can
268
be used to evaluate the release of the API to the medium as a function of the solubility
269
of the API 32 . Consequently, the gradient in the API concentration represents the driving
270
force in the mass transfer process in which the external mass-transfer coefficient (kext ) is the
271
most characteristic parameter. Calculations for both amorphous ITZ-GA and crystalline
272
raw ITZ revealed that the kext does not differ significantly, namely 0.245 h−1 and 0.312 h−1 13 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
273
respectively, indicating that the dissolution rate of the API is rather equal for both products
274
even though the apparent solubility differs almost ten times. This increase in the apparent
275
solubility highlights in fact the enhancement in the bioavailability of the amorphous ITZ-GA
276
product, which moreover remains stable without crystallizing from solution over the delivery
277
period.
278
Stability and recrystallization of amorphous glassy ITZ
279
As well-known, amorphous solids are by definition thermodynamically metastable, i.e. they
280
require an extra effort to keep their stability and therefore to exploit the promised enhanced
281
solubility of the API’s formulated in that way. To determine how recrystallization happens
282
in an amorphous itraconazole particle, glassy ITZ prepared as described in the experimental
283
section, which has been shown to be stable for more than six months (data not shown), was
284
redispersed in deionised water containing different amounts and type of excipients, namely
285
GA and PVA, for 96 hours. After this time, the suspension was filtered and the recovered
286
solids analysed by XRD. During the whole duration of the experiment, temperature was
287
kept constant at 25 ◦C and the stirring speed was set at 500 rpm.
288
Figure 6 presents all XRD patterns of the products obtained using as excipients both GA
289
(fig. 6a) and PVA (fig. 6b). From these results, it is evident that whereas with no excipient
290
recrystallization of glassy ITZ occurs, the selection of the right excipient and its addition into
291
the suspension, even at low concentrations, allows inhibiting the recrystallization. In fact,
292
comparing the patterns obtained using both excipients, and as expected from our previous
293
results, PVA is not capable to avoid the recrystallization of the glassy ITZ, even at a 1:1
294
ratio of glassy ITZ to excipient. On the other hand, ratios of 1:0.05 are sufficient to prevent
295
the recrystallization of the amorphous solid when using GA as excipient. In the latter case,
296
(see fig. 6a) the increase in the amount of excipient up to ratios 1:1 yields a second halo
297
in the XRD pattern, which falls within the 2θ angle range representative of pure GA. This
298
might be explained by the excess of GA that does not adsorb on the surface of the glassy 14 ACS Paragon Plus Environment
Page 14 of 35
Page 15 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
299
Crystal Growth & Design
ITZ and therefore remains free in solution.
300
In order to further validate the experimental observations and to gain further insight
301
into the recrystallization mechanisms, we performed molecular dynamics (MD) simulations
302
with two aims: providing a deeper understanding of the surface-initiated recrystallization
303
of amorphous glassy ITZ particles, and developing a rationale for the differences observed
304
experimentally in the stabilization effects of GA and PVA.
305
Surface recrystallization To address the first issue, we have performed a MD simulation
306
of a small amorphous particle with full atomistic detail (fig. 7a).
307
The experiments show that the recrystallization of amorphous ITZ nanoparticles at ambient
308
pressure occurs over rather long timescales, rendering a direct investigation of the crystal-
309
lization mechanism in the nanoparticle through MD practically unattainable. We observe
310
in fact, that in the amorphous phase at ambient temperature, the ITZ molecules tend to
311
form an entangled structure in which both diffusion and configurational rearrangements are
312
extremely slow, as typically observed in glassy systems 33,34 . Nevertheless, MD simulations
313
provide a molecular level description of the dynamics of ITZ molecules in the amorphous
314
state. In particular we can follow the dynamics of individual ITZ molecules within the
315
amorphous phase, thus computing their Mean Square Displacement as an index of their
316
propensity to move. The Einstein equation establishes a relationship between the diffusion
317
coefficient (D) and the Mean Square Displacement (MSD), namely D = MSD/(6t), that
318
holds rigorously in the long time limit 35 .
319
From our simulations, we observe that the diffusion coefficient is not constant within the
320
amorphous particle. In fact, it shows a rather marked dependence on the position within
321
the particle. As shown in Fig. 7c, molecules on the surface, characterized by a high solvent
322
exposure (right hand side of the figure), exhibit larger values of the diffusion coefficient
323
compared to molecules that are buried within the particle (low solvent exposure, left hand
324
side of the figure). ITZ molecules located on the surface of the particle have D values up to
15 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
325
one order of magnitude larger than those in the bulk. This observation is in agreement with
326
previous results reported by Zhu et al., where they observed surface diffusion faster than
327
bulk diffusion for indomethacin 36 .
328
Since recrystallization, i.e. the transition from amorphous state to crystalline state, im-
329
plies a reorganization of the ITZ molecules towards a higher level of order, molecular mobility
330
is a prerequisite for such a reorganization to occur. As a consequence, the key molecules that
331
trigger recrystallization are those that have the highest mobility, i.e. those on the surface of
332
the amorphous particles, as to the MD simulations have shown. Under the hypothesis that
333
there is a direct relationship between mobility, i.e. D, and recrystallization rate, we estimate
334
recrystallization rates at least one order of magnitude larger on the surface than in the bulk
335
of the particle. These results support the experimental observation of a recrystallization
336
process triggered at the particle surface. Adding an excipient that provides a coating for
337
the particle and avoids the direct exposure of ITZ molecules at the particle/solvent interface
338
results in a key factor towards obtaining a substantial slowing-down of the recrystallization
339
process.
340
ITZ-excipient interactions In order to investigate the interactions of the GA and PVA
341
excipients with the amorphous ITZ surface, we have simulated the adsorption of the excipient
342
on the surface of an amorphous ITZ particle, as well as its behaviour when dispersed in
343
aqueous solution. The model of the ITZ surface has been prepared by relaxing 40 ITZ
344
molecules randomly packed in a planar slab geometry. A single GA molecule and a PVA
345
oligomer composed of 20 monomeric units have been prepared in solution and allowed to
346
spontaneously adsorb on the surface, thus adopting a stable interacting configuration. The
347
adsorbed configurations of both GA and PVA excipients have been simulated for 200 ns. In
348
Fig. 8 we report two sample structures exhibiting the additive adsorbed on the surface of the
349
ITZ particle. The amorphous ITZ surface favors non polar interactions with the excipients.
350
The GA molecule has a very well defined hydrophilic head and hydrophobic tail. As shown
16 ACS Paragon Plus Environment
Page 16 of 35
Page 17 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
351
in Fig. 8, an isolated GA molecule in solution interacts with water molecules in a localized
352
region that can be identified as the polar, hydrophilic head. A large hydrophobic tail can
353
also be identified as the molecular region that does not significantly interact with water
354
molecules. The PVA oligomer exhibits instead a different interacting pattern within the
355
water environment. The hydroxyl groups are by construction distributed along the whole
356
polymer chain, and thus polar/apolar domains cannot be clearly identified. This difference
357
in the distribution of the polar moieties is reflected in the adsorbed configuration.
358
In its adsorbed configuration, GA has the apolar tail strongly interacting with the surface,
359
while the polar head fluctuates, while interacting with the water molecules in solution. PVA
360
exhibits larger flexibility instead: while its adsorbed configuration is maintained for hundreds
361
of nanoseconds, it is subject to fluctuations associated with the formation and breakage of
362
polar interactions with the solvent. These characteristics of the interaction between the
363
excipient and the ITZ surface determine a tighter binding of the GA on the surface, that
364
likely limits the surface-initiated recrystallization of ITZ amorphous particles. While PVA
365
also binds to the amorphous ITZ surface, it is characterized by much larger fluctuations both
366
in its structure and in the formation of hydrophobic interactions with the surface. These
367
observations seem to be in agreement with the recrystallization experiments and provide
368
further evidence to support the hypothesis that the recrystallization of the ITZ particles
369
is more effectively inhibited by excipient molecules that can establish stable interactions
370
with the particle surface as previous authors have suggested 3,37 , thus hindering the surface
371
reorganization that is considered to be the initial step towards ITZ recrystallization.
372
Conclusions
373
SFEE has been demonstrated as a feasible technique to manufacture totally amorphous
374
formulations of itraconazole as a function of the excipient used, whose correct selection allows
375
stable amorphous products that can therefore provide the promised enhanced solubility and
17 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
376
bioavailability. In fact, the in-vitro delivery tests have concluded that in the case of the stable
377
amorphous ITZ-GA product manufactured by SFEE, the apparent solubility is almost ten
378
times higher than the corresponding for crystalline ITZ.
379
Molecular dynamics simulations have proved that recrystallization of the amorphous ITZ
380
particle starts at its surface in the presence of water, highlighting that the addition of suitable
381
excipients, such as GA, allows an adequate adsorption of the excipient onto the ITZ particle
382
and hinders its recrystallization.
383
The work presented here not only shows the importance in the selection of the type of ex-
384
cipient to formulate an amorphous product of a low water-soluble API, but also it highlights
385
the relevance of evaluating the stabilizing effect of the excipients over the recrystallization
386
of the pure amorphous product when it is redispersed in water, such as for formulating a
387
pharmaceutical suspension or during dissolution. Indeed, the selection of the excipient plays
388
a crucial role in the recrystallization of the glassy itraconazole, which seems to start at the
389
surface of the particle, and must be carried out based on the molecular interactions between
390
the API and the excipient. Actually, a preliminary evaluation of the interactions between
391
excipients and amorphous material might allow to gain further insight into the affinity of
392
the excipient towards the particle surface, and hence, into its capability to inhibit recrystal-
393
lization in the presence of water.
394
Acknowledgements
395
The authors thank the group of Prof. Michele Parrinello for the scientific discussions and
396
the computational resources. The corresponding author thanks Junta de Comunidades de
397
Castilla-La Mancha (Spain) for the postdoctoral grant co-financed by the European Union
398
within the framework of 2007-2013 ERDF Operational Programme.
18 ACS Paragon Plus Environment
Page 18 of 35
Page 19 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
399
400
401
Crystal Growth & Design
References (1) Six, K.; Verreck, G.; Peeters, J.; Binnemans, K.; Berghmans, H. Thermochim. Acta 2001, 376, 175–181.
402
(2) Matteucci, M.; Paguio, J.; Miller, M.; Williams III, R.; Johnston, K. Highly Supersat-
403
urated Solutions from Dissolution of Amorphous Itraconazole Microparticles at pH 6.8.
404
Mol. Pharm. 2009, 6, 375–385.
405
(3) Alonzo, D.; Zhang, G.; Zhou, D.; Gao, Y.; Taylor, L. Understanding the behaviour of
406
amorphous pharmaceutical systems during dissolution. Pharm. Res. 2010, 27, 608–618.
407
(4) Six, K.; Verreck, G.; Peeters, J.; Augustijns, P.; Kinget, R. Int. J. Pharm. 2001, 213,
408
409
410
163–173. (5) Miller, D. A.; McConville, J. T.; Yang, W.; Williams III, R. O.; McGinity, J. W. J. Pharm. Sci. 2007, 96, 361–376.
411
(6) Barrett, A. M.; Dehghani, F.; Foster, N. R. Pharmaceut. Res. 2008, 25, 1274–89.
412
(7) Shekunov, B. Y.; Chattopadhyay, P.; Seitzinger, J.; Huff, R. Pharmaceut. Res. 2006,
413
414
415
416
23, 196–204. (8) Kluge, J.; Fusaro, F.; Muhrer, G.; Thakur, R.; Mazzotti, M. J. Supercrit. Fluids 2009, 48, 176–182. (9) Kluge, J.; Fusaro, F.; Mazzotti, M.; Muhrer, G. J. Supercrit. Fluids 2009, 50, 336–343.
417
(10) Kluge, J.; Joss, L.; Viereck, S.; Mazzotti, M. Chem. Eng. Sci. 2012, 77, 249–258.
418
(11) Margulis-Goshen, K.; Weitman, M.; Major, D. A. N. T.; Magdassi, S. J. Pharm. Sci.
419
420
421
2011, 100, 4390–4400. (12) Six, K.; Leuner, C.; Dressman, J.; Verreck, G.; Peeters, J.; Blaton, N.; Augustijns, P.; Kinget, R.; Mooter, G. V. D. J. Therm. Anal. Calorim. 2002, 68, 591–601. 19 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
422
(13) Six, K.; Berghmans, H.; Leuner, C.; Dressman, J.; Werde, K. V.; Mullens, J.;
423
Benoist, L.; Thimon, M.; Meublat, L.; Verreck, G.; Peeters, J.; Brewster, M.; Mooter, G.
424
V. D. Pharmaceut. Res. 2003, 20, 1047–1054.
425
426
(14) Fern´andez-Ronco, M. P.; Kluge, J.; Krieg, J.; Rodr´ıguez-Rojo, S.; Andreatta, B.; Luginbuehl, R.; Mazzotti, M.; Sague, J. J. Supercrit. Fluids 2014, 95, 204–213.
427
(15) Abdel-Mottaleb, M. M.; Lamprecht, A. Drug Dev. Ind. Pharm. 2011, 37, 178–84.
428
(16) The United States Pharmacopea, U. United States PharmacopeaConvention, Inc.,
429
430
431
432
433
434
435
436
437
438
439
Rockville, MD. 2005, (17) Mart´ınez, L.; Andrade, R.; Birgin, E. G.; Mart´ınez, J. M. J. Comput. Chem. 2009, 30, 2157–2164. (18) Jorgensen, W. L.; Chandrasekhar, J.; Madure, J. D.; Impery, R. W.; Klein, M. L. J. Chem. Phys. 1983, 926–935. (19) Wang, J.; Wolf, R.; Caldwell, J.; Kollman, P.; Case, D. J. Comput. Chem. 2004, 25, 1157–1174. (20) Cornell, W.; Cieplak, P.; Bayly, C.; Gould, I.; Merz, K.; Ferguson, D.; Spellmeyer, D.; Fox, T.; Caldwell, J.; Kollman, P. J. Am. Chem. Soc. 1995, 117, 5179–5197. (21) Stephens, P.; Devlin, F.; Chabalowski, C.; Frisch, M. J. Phys. Chem. 1994, 98, 11623– 11627.
440
(22) Bayly, C.; Cieplak, P.; Cornell, W.; Kollman, P. J. Phys. Chem. 1993, 97, 10269–10280.
441
(23) Frisch, M. J. et al. Gaussian 09 Revision A.1. Gaussian Inc. Wallingford CT 2009.
442
(24) Salomon-Ferrer, R.; Gotz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C. J. Chem.
443
444
Theory Comput. 2013, 9, 3878–3888. (25) Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. Comput. Phys. 1977, 23, 327–341. 20 ACS Paragon Plus Environment
Page 20 of 35
Page 21 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
445
(26) Case, D. A. et al. AMBER 12. 2012; http://ambermd.org/.
446
(27) Fusaro, F.; Kluge, J.; Mazzotti, M.; Muhrer, G. J. Supercrit. Fluids 2009, 49, 79–92.
447
(28) Gonzalez, A. V.; Tufeu, R.; Subra, P.; Inge, L.; Nord, P.; Jean, A.; Cle, B. J. Chem.
448
Eng. Data 2002, 492–495.
449
(29) Sun, W.; Mao, S.; Shi, Y.; Chiu Li, L.; Fang, L. Nanonization of Itraconazole by High
450
Pressure Homogenization: Stabilizer Optimization and Effect of Particle Size on Oral
451
Absorption. J. Pharm. Sci. 2011, 100, 3365–3373.
452
(30) Yang, W.; Johnston, K.; Williams III, R. Comparison of bioavailability of amorphous
453
versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur.
454
J. Pharm. Biopharm. 2010, 75, 33–41.
455
(31) Matteucci, M.; Miller, M.; Williams III, R.; Johnston, K. Highly Supersaturated Solu-
456
tions of Amorphous Drugs Approaching Predictions from Configurational Thermody-
457
namic Properties. J. Phys. Chem. B 2008, 112, 16675–16681.
458
459
460
461
(32) Cabezas, L. I.; Gracia, I.; Lucas, A. D.; Rodr´ıguez, J. F. Ind. Eng. Chem. Res. 2014, 40, 15374–15382. (33) Xiang, T.-X.; Anderson, B. Molecular dynamics simulation of amorphous indomethacin. Mol. Pharm. 2013, 10, 102–114.
462
(34) Gupta, J.; Nunes, C.; Jonnalagadda, S. A molecular dynamics approach for predicting
463
the glass transition temperature and plasticization effect in amorphous pharmaceuticals.
464
Mol. Pharm. 2013, 10, 4136–4145.
465
466
467
468
(35) Frenkel, D.; Smit, B. Understanding Molecular Simulation, 2nd ed.; Academic Press, Inc.: Orlando, FL, USA, 2001. (36) Zhu, L.; Brian, C.; Swallen, S.; Straus, P.; Ediger, M.; Yu, L. Surface Self-Diffusion of an Organic Glass. Phys. Rev. Lett. 2011, 106, 256103(1)–256103(4). 21 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
469
(37) Rumondor, A.; Taylor, L. Effect of Polymer Hygroscopicity on the Phase Behaviour
470
of Amorphous solid Dispersions in the Presence of Moisture. Mol. Pharm. 2010, 7,
471
477–490.
22 ACS Paragon Plus Environment
Page 22 of 35
Page 23 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
472
List of Tables
473
Table 1. Experimental conditions for PCA and SFEE runs. Solution flow refers to the flow
474
of the oil-in-water emulsion in the SFEE experiments.
475
23 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 24 of 35
Table 1: Experimental conditions for PCA and SFEE runs. Solution flow refers to the flow of the oil-in-water emulsion in the SFEE experiments.
Run #
Technique
P (bar)
T (◦C)
ITZ in oil phase (wt%)
1∗ 2∗ 3∗
PCA SFEE SFEE
100 80 80
40 45 45
1 5 5
∗
Excipient in water phase (wt%)
CO2 Flow (g/min)
Solution flow (mL/min)
– PVA (1.2) GA (1.2)
80 80 80
0.67 2 2
All the experiments represent the average of two replica runs.
24 ACS Paragon Plus Environment
Page 25 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
476
List of Figures
477
Figure 1:
478
Molecular structures of (a) itraconazole API; (b) glycyrrhizic acid (GA) excipient; (c) polyvinyl
479
alcohol (PVA) excipient.
480
Figure 2:
481
SEM images of (a) pure itraconazole as received from supplier, and (b) itraconazole product
482
obtained from PCA experiment (run 1). Scale bars indicate 100 µm.
483
Figure 3:
484
SEM images of the post-processed products collected from SFEE experiments at tlag of 0, 5
485
and 20 hours. a), b), and c) refer to the products manufactured using GA as excipient; and
486
d), e) and f) refer to those using PVA. White arrows underline the recrystallization at the
487
surface of the particles.
488
Figure 4:
489
Effect of the type of excipient in the evolution of SFEE product crystallinity as a function
490
of tlag . Bars indicate the experimental error of two replica experiments.
491
Figure 5:
492
Delivery profiles obtained from in-vitro tests of raw crystalline ITZ and the post-processed
493
SFEE product obtained using GA as excipient. Bars indicate the standard deviation.
494
Figure 6:
495
XRD patterns of the products collected after 96 hours of redispersing glassy ITZ in deionised
496
water. Percentages indicate the weight of excipient in the solid mixture. a) Glycyrrhizic acid;
497
b) Polyvinyl alcohol.
498
Figure 7:
499
MD simulations of an amorphous ITZ nanoparticle. The three parts of the figure provide
500
different information on the same simulation. Individual ITZ molecules are always associated
501
to one specific color; atoms are displayed as spheres when the focus is on the surface and
502
points connected by bonds when we look at the interior structure. This allows for a visual25 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
503
isation of the molecules within the nanoparticle as well as on its surface. a) Surface of the
504
nanoparticle. b) Section of the nanoparticle highlighting its amorphous internal structures.
505
c) Diffusion coefficient plotted against the average solvent exposure. Each point in the plot
506
represents a single ITZ molecule. Negative numbers in the solvent exposure represent the
507
ITZ molecules that do not enter in contact with the particle/solution interface.
508
Figure 8:
509
MD simulations of surfactants in solution (a,b) and interacting with the ITZ surface (c,d).
510
The water molecules within 0.3 nm of polar moieties of either GA or PVA molecules are ex-
511
plicitly represented, together with their VdW surface reported as a red transparent surface.
512
The ITZ surface in contact with the GA or the PVA molecules is represented in green. GA
513
both in solution (a) and adsorbed on the surface (c), interacts with water molecules in a
514
localised domain acting as a polar head. The PVA oligomer instead establishes polar interac-
515
tions with the solvent all along its chain both in solution (b) and adsorbed on the surface (d).
516
26 ACS Paragon Plus Environment
Page 26 of 35
Page 27 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
(a)
(b)
(c)
Figure 1: Molecular structures of (a) itraconazole API; (b) glycyrrhizic acid (GA) excipient; (c) polyvinyl alcohol (PVA) excipient.
27 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 28 of 35
(b)
(a)
Figure 2: SEM images of (a) pure itraconazole as received from supplier, and (b) itraconazole product obtained from PCA experiment (run 1). Scale bars indicate 100 µm.
28 ACS Paragon Plus Environment
ACS Paragon Plus Environment
29
2 mm
tlag = 0 h
e
b
3 mm
1 mm
tlag = 5 h
tlag = 5 h
f
c
5 mm
1 mm
tlag = 20 h
tlag = 20 h
Figure 3: SEM images of the post-processed products collected from SFEE experiments at tlag of 0, 5 and 20 hours. a), b), and c) refer to the products manufactured using GA as excipient; and d), e) and f) refer to those using PVA. White arrows underline the recrystallization at the surface of the particles.
d
1 mm
tlag = 0 h
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
a
Page 29 of 35 Crystal Growth & Design
Crystal Growth & Design
1 0 0 9 0 8 0
IT Z -P V A
7 0
C r y s ta llin ity ( % )
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 30 of 35
6 0 5 0 4 0 3 0 2 0 1 0
IT Z -G A 0 0
5
1 0
1 5
2 0
T im e ( h ) Figure 4: Effect of the type of excipient in the evolution of SFEE product crystallinity as a function of tlag . Bars indicate the experimental error of two replica experiments.
30 ACS Paragon Plus Environment
Page 31 of 35
1 0
IT Z -G A
1
IT Z (p p m )
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
R a w
IT Z
0 .1
0 .0 1 0
5 0
1 0 0
8 0 0
1 0 0 0
1 2 0 0
1 4 0 0
1 6 0 0
1 8 0 0
T im e ( m in )
Figure 5: Delivery profiles obtained from in-vitro tests of raw crystalline ITZ and the postprocessed SFEE product obtained using GA as excipient. Bars indicate the standard deviation.
31 ACS Paragon Plus Environment
ACS Paragon Plus Environment
32
Intensity (AU)
10
15
20
25
35
40
2 (degrees)
30
45
50
65
5
10
15
20
25
30
35
40
45
50
2 (degrees)
55
60
ITZ
ITZ
60
Glassy
Glassy
55
PVA
0%
5%
GA
0%
5%
Figure 6: XRD patterns of the products collected after 96 hours of redispersing glassy ITZ in deionised water. Percentages indicate the weight of excipient in the solid mixture. a) Glycyrrhizic acid; b) Polyvinyl alcohol.
5
19 %
19 %
9%
33 %
33 %
9%
50 %
(b) 50 %
Intensity (AU)
65
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
(a)
Crystal Growth & Design Page 32 of 35
Page 33 of 35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
Figure 7: MD simulations of an amorphous ITZ nanoparticle. The three parts of the figure provide different information on the same simulation. Individual ITZ molecules are always associated to one specific color; atoms are displayed as spheres when the focus is on the surface and points connected by bonds when we look at the interior structure. This allows for a visualisation of the molecules within the nanoparticle as well as on its surface. a) Surface of the nanoparticle. b) Section of the nanoparticle highlighting its amorphous internal structures. c) Diffusion coefficient plotted against the average solvent exposure. Each point in the plot represents a single ITZ molecule. Negative numbers in the solvent exposure represent the ITZ molecules that do not enter in contact with the particle/solution interface.
33 ACS Paragon Plus Environment
Crystal Growth & Design
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 8: MD simulations of surfactants in solution (a,b) and interacting with the ITZ surface (c,d). The water molecules within 0.3 nm of polar moieties of either GA or PVA molecules are explicitly represented, together with their VdW surface reported as a red transparent surface. The ITZ surface in contact with the GA or the PVA molecules is represented in green. GA both in solution (a) and adsorbed on the surface (c), interacts with water molecules in a localised domain acting as a polar head. The PVA oligomer instead establishes polar interactions with the solvent all along its chain both in solution (b) and adsorbed on the surface (d).
34 ACS Paragon Plus Environment
Page 34 of 35
Page 35 of 35
For Table of Contents Use Only
Study of the preparation of amorphous Itraconazole formulations Mar´ıa P. Fern´andez-Ronco,∗,†,¶ Matteo Salvalaglio,†,‡ Johannes Kluge,†,§ and Marco Mazzotti† ETH Zurich, Institute of Process Engineering, Sonneggstrasse 3, 8092 Zurich, Switzerland, and Facolt` a di Informatica, Istituto di Scienze Computazionali Universit` a della Svizzera Italiana, 6900 Lugano, Switzerland E-mail:
[email protected] Phone: +41 44 632 22 45. Fax: +41 44 632 11 41
AMORPHOUS ITRACONAZOLE Redispersed in water
+ Glycyrrhizic acid
+ Polyvinyl alcohol STABLE
NOT STABLE
5% 0% GA Glassy ITZ 5
50 % 33 % 19 % 9% 5% 0%
Intensity (AU)
50 % 33 % 19 % 9%
Intensity (AU)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Crystal Growth & Design
PVA Glassy ITZ 5
10 15 20 25 30 35 40 45 50 55 60 65
2θ(degrees)
10 15 20 25 30 35 40 45 50 55 60 65
2θ(degrees)
Synopsis – Schematic representation of the effect of excipients in the stability to recrystallize of amorphous pure glassy itraconazole when redispersing it in water.
∗
To whom correspondence should be addressed ETH Zurich–Institute of Process Engineering ‡ ETH Zurich–Istituto di Scienze Computazionali ¶ Current address: EMPA, Laboratory for Advanced Fibers, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland. E-mail:
[email protected] § Current address: Novartis Pharma AG, 4056 Basel, Switzerland. †
1 ACS Paragon Plus Environment